Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis– Related Diabetes
Authors' conclusion
Adults with CFRD had improved glucose control without an increase in CGM-measured hypoglycemia with the BP compared with their UC, suggesting that this may be an important therapeutic option for this patient population.
Study context
- Population
- Adults with cystic fibrosis-related diabetes (CFRD); no restrictions on diet or activitycrossover
- Participants
- 20 adults
- Comparison
- iLet bionic pancreas vs usual care
- Primary endpoint
- Percent time sensor glucose in target range 70-180 mg/dL (TIR)
- Follow-up
- Days 3-14 of each arm
Methodological detailssingle-center, open-label, random-order
- Single-center
- Open-label
- Random-order
Primary result
As reported in the abstract
TIR · days 3-14
P = 0.001
Secondary outcomes
Mean CGM glucose · lower with BP
P = 0.007
Safety
Self-reported symptomatic hypoglycemia episodes · higher with BP
P = 0.01
Events
| Outcome | BP | UC |
|---|---|---|
| DKA or severe hypoglycemia | 0 | 0 |
- Percent time sensor glucose <54 mg/dL · no significant difference
- P = 1.0
Original publication
Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis– Related Diabetes. Diabetes Care. Published 24 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →